Transparency data

Non-tech summaries 2016: projects on cancer

Projects granted during 2016 that have a primary purpose of translational and applied research - human cancer.

• From: Home Office
• Published: 21 December 2017

Documents

Non-technical summaries: projects granted in 2016, volume 16

PDF, 1.55 MB, 250 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email [email protected]. Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

This document outlines the projects granted under the Animals (Scientific Procedures) Act 1986 during 2016 with a primary purpose of translational and applied research - human cancer.

The following projects were granted:

• gene transfer to rodents to test for adverse effects and correct disease (gene therapy, vectors, cancer, friedreich ataxia.)

• evaluation of novel anticancer agents (evaluation, novel, anticancer, agents)

• regulatory mechanisms in normal haematopoiesis (stem cells, haematopoiesis, leukaemia)

• development of new biological anticancer agents (cancer, virotherapy, targeted, biologic)

• evaluating new cancer therapies (lung cancer models, drug discovery)

• thermosensitive nanoparticles for cancer therapy (cancer treatment, drug development, liposomes, theranostics)

• mouse models of pancreatic cancer and therapy (pancreatic cancer, treatment, tumour stroma)

• anticancer drug discovery and target validation (anticancer, drug, discovery, target, validation)

• modelling bone-tumour interactions in metastasis (metastasis, breast/prostate cancer, myeloma, bone)

• novel biologicals for tumour immunotherapy (tumour immunotherapy; antibodies; adjuvants; targeted delivery)

• signal transduction in lung cancer pathogenesis (lung, cancer, autophagy, NF-κB, therapy)

• molecular imaging in cancer (molecular, imaging, cancer)

• development of new anticancer therapies (cancer, drugs, translation, biomarkers)

• mouse models of tumour growth and progression (cancer, metastasis, therapy, transplantation)

• in vivo imaging in cancer models (imaging, cancer, diagnosis, therapy)

• cancer therapy-efficacy licence (oncology, tumour, efficacy, pharmacodynamic)

• understanding and targeting the drivers of malignancy (cancer, prevention, treatment, metastasis)

• regulation of normal and malignant blood cells (stem cell, leukaemia, microenvironment, niche, self- renewal)

• oncolytic hsv as an anti –cancer therapy (oncolytic , cancer therapy)

• stem cell function in tissue regeneration, diabetes and cancer (stem cells, cancer, diabetes)

• modelling cancer predisposition by BRCA2 mutations (cancer; genetic alteration; pancreatic cancer)

• genetic analysis of tumour development (cancer, tumour, inflammation, therapy, imaging)

• tumour models for therapy of advanced cancers (tumour, metastasis, novel drugs, imaging)

• understanding inflammation, fibrosis and cancer (scarring, cancer, drugs)

• signalling pathways in cancer, inflammation, and metabolism (NF-κB, cancer, therapy, inflammation, metabolism)

• platelets and cardioprotection in cancer (platelets, cancer, cardio-toxicity, metastasis)

• oncology models (oncology, immunology, therapeutics)

• haematopoietic and leukaemia stem cell regulation (haematopoiesis; stem cells; leukaemia; lymphoma; leukaemia stem cells; novel therapy)

• novel strategies to target cancer (cancer, microenvironment, immunotherapy)

• engineered mice for gene function analysis (cancer, gene function, mouse, embryonic stem cells, embryonic development, developmental defect)

• studying the origins of cancers from stem cells (paediatric, adult, epithelial, cancer, biology)

• xenopus as a model for development and drug discovery (xenopus, developmental biology, cancer, stem cell biology)

• hypoxia and angiogenesis in cancer therapy (hypoxia, angiogenesis, cancer)

• mechanisms of metastasis (metastasis, myeloid cells, coagulation, extracellular matrix)

• induction of anti-tumour immunity (cancer, white cells, immune-therapy)

• modelling cancer biology and therapy in mouse (breast mammary cancer metastasis xenograft)

• establishment of patient derived xenografts from biopsy samples (cancer, tumour, biopsy, tissue generation)

• pancreatic cancer: biology and therapy (pancreatic cancer, pancreatitis, therapeutic targets)

• colorectal cancer initiation and progression (colorectal, cancer, RNA, genes)

• model systems to improve cancer immunotherapy (cancer, immotherapy, mouse)

• implantable microsystems for cancer therapy

• study and manipulation of immune-regulatory receptors to improve cancer therapeutics (cancer, immunology, immunotherapy, checkpoint)

• preclinical evaluation of cancer therapeutics (cancer, chemotherapy, immune-oncology)

• personalised tumour graft (tumour, human, personalised)

• assessment of novel cancer therapeutics (tolerability, pharmacokinetics, cancer, mouse, rat)

• enhancement of targeted radiotherapy of cancer (targeted, radiotherapy)

• the molecular basis of lymphoma and leukaemia (lymphoma, leukaemia, mouse models)

• pre-clinical assessment of new anticancer agents (oncolytic virus, immustimulation, vaccine, combination treatment, anti-cancer agent)

• analysing cancer: immune cell interactions involved in metastasis (cancer, imagine, animal models, immune system, cell signalling)

• generating new mouse models of human cancer (cancer, model, transgenic)

• skin cancer survival in the aging population (melanoma, microenvironment, squamous cell carcinoma, aging)

• mouse models for tumour stem cells and anti-tumour efficacy studies (cancer, brain tumours, tumour growth, invasion)

• developing an ocular melanoma model for drug discovery (ocular melanoma, uveal melanoma, patient derived xenograft MEK)

• adoptive T cell therapy for cancer (cancer, T lymphocytes, T-cell receptor, immunotherapy, adoptive therapy)

• drug evaluation in pre-clinical oncology models (cancer, pre-clinical, efficacy, models, imaging)

• cellular immunotherapy of disease (gene-modified immune cells, tumour immunity)

• MYB proteins and myeloid disease susceptibility (stem cells, bone marrow, blood cells, leukaemia, ageing)

• interrogating the immunology of cancer and the development of cancer therapeutics (vaccine, therapeutics, cancer, immune cells)

• pancreatic cancer – improving our understanding and therapeutic options (pancreatic cancer, therapeutic, genotype/phenotype)

• vaccine development and immunotherapy (cancer therapy, vaccine, therapeutic antibody)

• regulation of tumour growth and metastasis by sodium channels (antiepileptic drugs, breast cancer, invasion, metastasis, sodium channels)

• immune cell mechanisms in cancer and infection (infection, cancer, immunology)

• immune and biological therapies for cancer (cancer, virus, immune system)

• modelling a gene family in human disease (cancer, heart, skin, inflammation)

• cancer therapy – enabling licence (tolerability, pharmacokinetics, tumour, surrogate)

• sarcoma, bone niche, microenvironment and therapy (cancer, microenvironment, biomarkers, therapy)

• hematopoiesis in development, aging and malignancy (stem cells, development, leukemia, aging, transplantation)

• in vivo evaluation of enadenotucirev derived viruses (oncolytic, adenovirus, cancer, immunotherapy)

• normal and leukemic blood cell development (stem cells, infant leukaemia, transplantation)

• regeneration/neoplasia of nervous system and muscle (stem cells, organ regeneration, brain tumour)

Published 21 December 2017